Publicaciones en colaboración con investigadores/as de Gustave Roussy Cancer Campus (25)

2022

  1. Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials

    European Journal of Cancer, Vol. 163, pp. 98-107

2021

  1. Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors

    Cancers, Vol. 13, Núm. 15

  2. ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors

    International Journal of Gynecological Cancer, Vol. 31, Núm. 7, pp. 961-982

  3. ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors

    Ultrasound in Obstetrics and Gynecology

  4. Intratumoural administration and tumour tissue targeting of cancer immunotherapies

    Nature Reviews Clinical Oncology, Vol. 18, Núm. 9, pp. 558-576

  5. Patterns of progression in patients treated for immuno-oncology antibodies combination

    Cancer Immunology, Immunotherapy, Vol. 70, Núm. 1, pp. 221-232

2020

  1. Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types

    Cancer Medicine, Vol. 9, Núm. 8, pp. 2643-2652

  2. Postoperative Radiation Therapy in Patients with Extracranial Chondrosarcoma: A Joint Study of the French Sarcoma Group and Rare Cancer Network

    International Journal of Radiation Oncology Biology Physics

2019

  1. Met receptor amplification drives resistance to anti-egfr therapies

    Journal of Immunotherapy and Precision Oncology, Vol. 2, Núm. 4, pp. 152-155

2018

  1. Are phase I trials safe for older patients?

    Journal of Geriatric Oncology, Vol. 9, Núm. 2, pp. 87-92

  2. Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours

    European Journal of Cancer, Vol. 95, pp. 68-74

  3. Locally advanced cervical cancer with bladder invasion: Clinical outcomes and predictive factors for vesicovaginal fistulae

    Oncotarget, Vol. 9, Núm. 10, pp. 9299-9310

2017

  1. 3D waterfall plots: A better graphical representation of tumor response in oncology

    Annals of Oncology

  2. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)

    European Journal of Cancer, Vol. 84, pp. 202-211

  3. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

    European Journal of Cancer, Vol. 84, pp. 212-218

2016

  1. Anti-PD1-induced pneumonitis: Capturing the hidden enemy

    Clinical Cancer Research, Vol. 22, Núm. 24, pp. 5956-5958

2015

  1. Intraoperative Radiotherapy for Gastrointestinal Malignancies: Contemporary Outcomes With Multimodality Therapy

    Current Oncology Reports, Vol. 17, Núm. 1

2014

  1. Bibliometrics of intraoperative radiotherapy: Analysis of technology, practice and publication tendencies

    Strahlentherapie und Onkologie, Vol. 190, Núm. 12, pp. 1111-1116

  2. Outcome and toxicity using helical tomotherapy for craniospinal irradiation in pediatric medulloblastoma

    Clinical and Translational Oncology, Vol. 16, Núm. 1, pp. 96-101

  3. Post-chemoradiation intraoperative electron-beam radiation therapy boost in resected locally advanced rectal cancer: Long-term results focused on topographic pattern of locoregional relapse

    Radiotherapy and Oncology, Vol. 112, Núm. 1, pp. 52-58